STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
Dutch antitrust regulators are investigating allegations that Biogen may have abused its dominant position in the market for multiple sclerosis treatments and associated blood tests.
- The Netherlands Authority for Consumers and Markets, also known by its Dutch acronym ACM, is probing whether the company reserved a test for patients who are treated with Tysabri, its MS drug, and refusing to make the test available to patients on rival medications, such as Tyruko, a biosimilar version that is sold by Sandoz.
- Continue to STAT+ to read the full story….
Biogen developed a test for the virus and provides it free of charge — and exclusively — to patients receiving Tysabri.
Patients who are treated with Tysabri, Biogen’s biggest-selling medicine, must be regularly tested for the risk of developing progressive multifocal leukoencephalopathy, an infection caused by a virus that may be fatal or result in severe disability.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →